Author Question: In the long run, firms in monopolistic competition produce at a level that is ________ the efficient ... (Read 70 times)

j.rubin

  • Hero Member
  • *****
  • Posts: 557
In the long run, firms in monopolistic competition produce at a level that is ________ the efficient scale of output.
 
  A) less than
  B) equal to
  C) more than
  D) All of the above are possible depending on market conditions.

Question 2

The concept of diminishing marginal rate of substitution indicates that
 
  A) as the consumption of good X increases, individuals are willing to give up an increasing amount of good Y in order to obtain one more unit of good X.
  B) as the consumption of good X increases, individuals are willing to give up a decreasing amount of good Y in order to obtain one more unit of good X.
  C) along an indifference curve, a consumer prefers the consumption combinations moving to the northwest along the curve.
  D) None of the above answers is correct.



nathang24

  • Sr. Member
  • ****
  • Posts: 314
Answer to Question 1

A

Answer to Question 2

B



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question


 

Did you know?

More than 4.4billion prescriptions were dispensed within the United States in 2016.

Did you know?

The first documented use of surgical anesthesia in the United States was in Connecticut in 1844.

Did you know?

There used to be a metric calendar, as well as metric clocks. The metric calendar, or "French Republican Calendar" divided the year into 12 months, but each month was divided into three 10-day weeks. Each day had 10 decimal hours. Each hour had 100 decimal minutes. Due to lack of popularity, the metric clocks and calendars were ended in 1795, three years after they had been first marketed.

Did you know?

The types of cancer that alpha interferons are used to treat include hairy cell leukemia, melanoma, follicular non-Hodgkin's lymphoma, and AIDS-related Kaposi's sarcoma.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library